Drugs / E5564
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00756912 | Sep → Nov 2008 | leukemia | Eisai Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT00046072 | Oct 2001 → Apr 2005 | infectious disease with sepsis | Eisai Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2011-01-25 | Eisai Inc. | Results PHASE Ⅲ STUDY FOR SEVERE SEPSIS TREATMENT ERITORAN (E5564) DOES NOT MEET PRIMARY ENDPOINT eisai.com ↗
The decision was based on the fact that the trial, a Phase III study conducted in patients with severe sepsis, did not meet its primary endpoint of 28-day all-cause mortality. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2011-01-25 | Eisai Inc. | PHASE Ⅲ STUDY FOR SEVERE SEPSIS TREATMENT ERITORAN (E5564) DOES NOT MEET PRIMARY ENDPOINT eisai.com ↗ |
| 2010-03-26 | Eisai Inc. | Eisai to Continue Eritoran (E5564) Phase Ⅲ Severe Sepsis Trial eisai.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E5564 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00756912 ↗ |
| Route | Intravenous | “Intravenous E5564” NCT00046072 ↗ |